Status:
RECRUITING
Neuromodulation of the Fear Extinction Circuit Using Temporally and Anatomically Specific TMS in Humans
Lead Sponsor:
The University of Texas Health Science Center, Houston
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
PTSD
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
This study aims to explore the mechanisms of how transcranial magnetic stimulation (TMS) impacts fear circuits. The overarching objectives are to understand how varying TMS parameters affect targeted ...
Detailed Description
The experiments proposed are aimed to understand how timing and location of transcranial magnetic stimulation (TMS) in humans will impact their ability to reduce conditioned fear responses and impact ...
Eligibility Criteria
Inclusion
- Willing and able to provide informed consent.
- Inclusion Criteria for PTSD Subjects - Diagnosis of current PTSD
- Healthy Controls (HC) - no current psychiatric disorders ("Axis I" disorders)
Exclusion
- Lifetime history of seizure or significant head trauma or other significant neurologic disease (e.g., tic disorder)
- History of serious/significant psychiatric diagnoses ("Axis I" diagnoses)
- Current significant suicidal ideation, plan or intent or suicidal behavior in past 6 months based on CSSRS and clinical judgment or Self-injurious behavior that involves suicidal intent, requires medical attention, or occurs daily
- Use of neuroleptics within one year prior to study
- Current substance use
- Pregnancy (to be ruled out by urine β-HCG).
- Metallic implants or devices contraindicating magnetic resonance imaging.
- Currently taking medications that lower the seizure threshold. These include antipsychotics, high dose theophylline or stimulants such as methylphenidate. Patients taking bupropion must be on a stable dose (\*last 3 months) and take less than or equal to 300 mg/day.
- Implanted devices in subject's head (shunts, cochlear implants); metal in subject's head (other than dental implants).
- High risk of adverse emotional or behavioral reaction, and/or an inability to understand study procedures or the informed consent process
- Additional exclusion criteria for Healthy controls (HC) group: Current psychiatric diagnosis ("Axis I" diagnosis)
Key Trial Info
Start Date :
February 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2027
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT05368987
Start Date
February 1 2022
End Date
September 30 2027
Last Update
April 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UTHealth Houston
Houston, Texas, United States, 77054